Company · CI
The Cigna Group
Name as listed on its exchange; filed with the SEC as Cigna Group.
Nasdaq's symbol directory lists CI on the New York Stock Exchange as “The Cigna Group Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 5 occasions ($65.7M); 3 planned-sale notices; 6 congressional trade disclosures; 4 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Cordani David, Chairman & CEO sold $59.1M
- Jones Nicole S, EVP, Chief Administrative Officer and Chief Human Resources Officer sold $6.1M
- Kates Jamie G, Chief Accounting Officer sold $268K
- Neville Everett, EVP, Special Advisor to the CEO sold $175K
Every trade (5)
- SELLNeville Everett, EVP, Special Advisor to the CEO sold $175K
- SELLJones Nicole S, EVP, Chief Administrative Officer and Chief Human Resources Officer sold $749K
- SELLJones Nicole S, EVP, Chief Administrative Officer and Chief Human Resources Officer sold $5.4M
- SELLKates Jamie G, Chief Accounting Officer sold $268K
- SELLCordani David, Chairman & CEO sold $59.1M
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Neville Everett $175K
- Jones Nicole S $748K
- Jones Nicole S $5.4M
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Alan Armstrong (R-OK): Purchase $1,001 - $15,000
- Jared Moskowitz (D-FL23): Sale $1,001 - $15,000
- Jared Moskowitz (D-FL23): Sale $1,001 - $15,000
- Gilbert Cisneros (D-CA31): Sale $1,001 - $15,000
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
- Julie Johnson (D-TX32): Sale $1,001 - $15,000
Executive branch · OGE Form 278-T
Reported by the President
10 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports
- Sale: The Cigna Group $100,001 – $250,000
- Sale: THE CIGNA GROUP $1,001 – $15,000
- Sale: THE CIGNA GROUP $1,001 – $15,000
- Purchase: The Cigna Group $100,001 – $250,000
- Purchase: THE CIGNA GROUP $1,001 – $15,000
- Sale: THE CIGNA GROUP $1,001 – $15,000
- Sale: THE CIGNA GROUP $1,001 – $15,000
- Purchase: THE CIGNA GROUP $1,001 – $15,000
- Purchase: THE CIGNA GROUP $1,001 – $15,000
- Sale: THE CIGNA GROUP $1,001 – $15,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 5, 2026
- Departure or appointment of directors or officers Oct 9, 2026
- Regulation FD disclosure Sep 30, 2026
- Results of operations and financial condition Jul 30, 2026
Lobbying · Senate LDA reports
Lobbying filed
6 quarterly lobbying reports for 2026 naming The Cigna Group as the client: 1 filed by the company itself, 5 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- RED+BLUE STRATEGIES no amount stated
- The company itself $3.5M
- ATLAS CROSSING LLC $60K
- BELLWETHER GOVERNMENT AFFAIRS LLC $60K
- BANNER PUBLIC AFFAIRS, LLC $20K
- WILMER CUTLER PICKERING HALE AND DORR LLP no amount stated
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.